Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Assets Average (2021 - 2025)

Caribou Biosciences has reported Assets Average over the past 5 years, most recently at $185.2 million for Q4 2025.

  • Quarterly Assets Average fell 43.69% to $185.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $185.2 million through Dec 2025, down 43.69% year-over-year, with the annual reading at $244.3 million for FY2025, 34.45% down from the prior year.
  • Assets Average was $185.2 million for Q4 2025 at Caribou Biosciences, down from $207.9 million in the prior quarter.
  • Over five years, Assets Average peaked at $452.2 million in Q4 2021 and troughed at $185.2 million in Q4 2025.
  • The 5-year median for Assets Average is $373.5 million (2022), against an average of $356.9 million.
  • Year-over-year, Assets Average skyrocketed 32.21% in 2022 and then plummeted 43.69% in 2025.
  • A 5-year view of Assets Average shows it stood at $452.2 million in 2021, then decreased by 14.57% to $386.3 million in 2022, then increased by 15.16% to $444.9 million in 2023, then fell by 26.08% to $328.8 million in 2024, then crashed by 43.69% to $185.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Assets Average are $185.2 million (Q4 2025), $207.9 million (Q3 2025), and $247.3 million (Q2 2025).